# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE

A. 510(k) Number: K070265   
B. Purpose for Submission: Premarket notification 510(k)   
C. Measurand: Herpes simplex virus type 1 and type 2 (HSV-1 and HSV-2) D. Type of Test: Cell culture confirmation, by immunofluorescence using fluoresceinated monoclonal antibodies (MAbs).   
E. Applicant: Diagnostic Hybrids, Inc.

# F. Proprietary and Established Names:

Proprietary Name: ${ \boldsymbol { \mathrm { D } } } ^ { 3 }$ DFA Herpes Simplex Virus Identification and Typing Kit Common Name: Fluorescent antibody test for ID and typing HSV-1 and HSV-2 from cell culture

# G. Regulatory Information:

1. Regulation section: 866.3305 Herpes simplex virus serological reagents

2. Classification: Class II

3. Product code: GQN [Antigens, CF (including CF control), herpesvirus hominis, 1, 2]

4. Panel: Microbiology (83)

# H. Intended Use:

1. Intended use(s): The Diagnostic Hybrids ${ \boldsymbol { \mathrm { D } } } ^ { 3 }$ DFA Herpes Simplex Virus Identification and Typing Kit is intended for use in the qualitative detection and typing of human herpes simplex virus type 1 and type 2 (HSV-1 and HSV-2) in cell cultures by immunofluorescence using fluoresceinated monoclonal antibodies (MAbs). Negative results do not preclude an infection and should not be used as the sole basis for diagnosis, treatment or other management decisions.

Performance using direct specimen testing has not been evaluated.

2. Indication(s) for use: Same as Intended Use.

3. Special conditions for use statement(s): For prescription use only.

4. Special instrument requirements: This device requires the use of a fluorescence microscope to read device stained cultures. One should use with the correct filter combination for FITC (excitation peak $= 4 9 0 \mathrm { n m }$ , emission peak $= 5 2 0 \mathrm { n m }$ ).

# I. Device Description:

The HSV-1 MAbs were developed using HSV-1(f) cell lysate as immunogen – one has been determined to be directed against HSV-1 glycoprotein C1, the antigen to the other is undetermined. The HSV-2 MAbs were developed using a HSV-2 recombinant glycoprotein G immunogen.

1. HSV-1 DFA Reagent – One dropper bottle containing a blend of two fluorescein labeled murine monoclonal antibodies directed against HSV-1 specific glycoproteins. The HSV-1 MAbs were developed using HSV-1(f) cell lysate as immunogen – one MAb has been determined to be directed against HSV-1 glycoprotein G1 (gG1), the antigen to the other is undetermined. The buffered, stabilized, aqueous solution contains Evan’s Blue as a counter-stain and $0 . 1 \%$ sodium azide as preservative.

2. HSV-2 DFA Reagent – One dropper bottle containing a blend of two fluorescein labeled murine monoclonal antibodies directed against HSV-2 specific glycoproteins. The HSV-2 MAbs were developed using a HSV-2 recombinant glycoprotein C immunogen. The buffered, stabilized, aqueous solution contains Evan’s Blue as a counter-stain and $0 . 1 \%$ sodium azide as preservative.

3. HSV-1/HSV-2 Antigen Control Slides - Individually packaged control slides containing wells with cell culture derived positive and negative control cells. Each slide consists of four wells containing acetone fixed cells; two wells of uninfected cells and one well each of HSV-1 infected cells and HSV-2 infected cells. Each slide is intended to be stained only one time.

4. PBS Concentrate - A 40X concentrate consisting of $4 \%$ sodium azide in phosphate buffered saline (after dilution to 1X in water, the concentration of sodium azide in the solution is $0 . 1 \%$ ).

5. Mounting Fluid - An aqueous, buffered, stabilized solution of glycerol and $0 . 1 \%$ sodium azide.

# J. Substantial Equivalence Information:

1. Predicate device name(s): Pathodx® Herpes Typing Kit

2. Predicate K number(s): K904167

3. Comparison with predicate:

<table><tr><td colspan="3" rowspan="1">Similarities</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Device</td><td colspan="1" rowspan="1">Predicate</td></tr><tr><td colspan="1" rowspan="1">Intended Use</td><td colspan="1" rowspan="1">For the qualitative detection ofherpes simplex virus (HSV) typesHSV-1 or HSV-2 in cell culturesby immunofluorescence usingfluoresceinated monoclonalantibodies. Negative results donot preclude an infection andshould not be used as the solebasis for diagnosis, treatment orother management decisions.Performance using directspecimen testing has not beenevaluated.</td><td colspan="1" rowspan="1">Remel PathoDx Herpes TypingKit is an immunofluorescencetest designed for the detectionand typing of herpes simplexvirus types I and II (HSV-1 andHSV-11) in direct clinicalspecimens and followinggrowth in tissue culture. Cultureconfirmation slides and shellvial assays may undergodetection and typing with abivalent staining procedure.</td></tr><tr><td colspan="1" rowspan="1">Basic principle</td><td colspan="1" rowspan="1">Direct Fluorescent Antibody(DFA) test - Immunofluorescenceusing fluoresceinated MAbs.</td><td colspan="1" rowspan="1">DFA (Direct FluorescentAntibody) test -Immunofluorescence usingfluoresceinated MAbs.</td></tr><tr><td colspan="1" rowspan="1">Antibody</td><td colspan="1" rowspan="1">A blend of two fluoresceinlabeled murine monoclonalantibodies against HSV-1 andtwo against HSV-1. Specificglycoproteins with weredeveloped using HSV-1(f) celllysate as immunogen  one MAbhas been determined to bedirected against HSV-1glycoprotein C1; the antigen tothe other is undetermined.The HSV-2 MAbs weredeveloped using two fluoresceinlabeled murine HSV-2recombinant glycoprotein Gimmunogens.</td><td colspan="1" rowspan="1">The HSV-I antibody is a blendof two monoclonal antibodieswhich react with polypeptideshaving 85K and 142K daltonmolecular weights. The HSV-IItyping reagent contains twomonoclonal antibodies, one thatrecognizes a 79K daltonpolypeptide and the other a 41Kdalton polypeptide molecule.</td></tr><tr><td colspan="1" rowspan="1">Instrumentation(required but notprovided)</td><td colspan="1" rowspan="1">Fluorescence microscope withthe correct filter combination forFITC (excitation peak = 490 nm,emission peak = 520 nm).</td><td colspan="1" rowspan="1">Fluorescence microscope withthe correct filter combinationfor FITC (excitation peak = 490nm, emission peak = 520 nm).</td></tr><tr><td colspan="1" rowspan="1">Sample type</td><td colspan="1" rowspan="1">Specimens of vesicular fluid;swabbed areas or lesionscontained in transport medium</td><td colspan="1" rowspan="1">Specimens of vesicular fluid;swabbed areas or lesionscontained in transport medium.</td></tr><tr><td colspan="3" rowspan="1">Differences</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Device</td><td colspan="1" rowspan="1">Predicate</td></tr><tr><td colspan="1" rowspan="1">Procedural</td><td colspan="1" rowspan="1">Immunofluorescence testingfollowing amplification in cellculture only.</td><td colspan="1" rowspan="1">Results are consideredpresumptive for identificationof HSV from direct patientspecimens usingfluoresceinated monoclonalantibodies. All direct clinicalspecimens which are negativeor have inadequate numbers ofcells must be re-evaluated bycell culture.</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable): N/A

L. Test Principle: A suspected specimen is inoculated into tube culture, shell vials or multi-well plates coated containing a monolayer of cells known to be sensitive to HSV. When infected with HSV, a characteristic deterioration of cells, termed cytopathic effect (CPE), can be observed. Tube culture can take several days before CPE is evident. However, the rate of isolation may be enhanced including a decreased time for identification and typing of inoculated specimens by centrifugation in shell vials or multi-well plates. Monolayers are fixed in acetone with a slide(s) prepared from tube culture scrapings or from shell vials or multi-well plates.

The ${ \boldsymbol { \mathrm { D } } } ^ { 3 }$ DFA HSV-1 or HSV-2 Reagents are added to separate monolayers. After incubating, the stained cells are washed and, covered with a supplied Mounting Fluid. The fixed monolayers are examined using a fluorescence microscope. The HSV-1 and HSV-2 DFA reagents contain Evan’s Blue as a counter-stain. HSV-1 or HSV-2 infected cells will both stain with a characteristic bright apple-green fluorescence distinguished from the counter-stained uninfected cells by a dull red fluorescence.

# M. Performance Characteristics (if/when applicable):

2. Analytical performance:

a. Precision/Reproducibility: Not applicable.

b. Linearity/assay reportable range: Not applicable.

c. Traceability, Stability, Expected values (controls, calibrators, or methods): Not applicable.

d. Detection limit: This testing is not considered necessary during premarket notification process because performance testing has been done using a comparative device in amplified cell culture (cell culture is not part of the review process for this device).

e. Analytical specificity:

i. Analytical specificity was evaluated by staining cultures infected with a number of ATCC reference HSV-1 and HSV-2 strains and found to react with all of them. The $\mathrm { D } ^ { 3 } \mathrm { H S V { - } } 1$ and HSV-2 DFA reagents were tested for cross-reactivity against a wide variety of other microorganisms and cells. No cross-reactivity was observed for 59 virus strains (cultured and processed for staining) or for 17 host culture cell types. Conditions for cross-reactivity testing were achieved by using the $\mathrm { \dot { D } } ^ { 3 } \mathrm { H S V { - } } 1$ or HSV-2 DFA Reagent along with relatively high titers of microorganisms. The DFA Reagents were prepared at 1.5X the concentration that is provided in the kit.

1. Depending on the particular virus, 500 to $7 1 5 \mathrm { T C I D } _ { 5 0 }$ viruses were inoculated into multi-well plate cultures and incubated for 24 hours, processed and stained with the 1.5X DFAs according to the procedure detailed in the product insert. Stained cells were examined at $2 0 0 \mathbf { x }$ magnification. Cell cultures were stained as confluent monolayers. Bacteria and yeast were cultured, processed as suspensions, then spotted on microscope slides (at CFUs ranging from $6 . 4 \mathrm { x } { 1 0 } ^ { 4 }$ to $\dot { 2 . 9 3 } \mathrm { x } 1 0 ^ { 7 } / \mathrm { w e l l }$ in a $1 0 ~ \mu \mathrm { L }$ dot, depending on the bacterium), then stained with the 1.5X DFAs according to the procedure in the product insert.

2. Twenty-seven (27) bacterial cultures, one yeast and one protozoan culture were stained and examined for cross-reactivity, including Staphylococcus aureus, a protein-A-producing bacterium. Staining of S. aureus appeared as small points of fluorescence while all other cultures were negative. [Protein A will specifically bind to the Fc portions of conjugated antibodies. Such binding can be distinguished from viral antigen binding on the basis of morphology, i.e., S. aureusbound fluorescence appears as small ${ \sim } 1$ micron diameter), bright dots.]

Results from previously described cross-reactivity testing for microbiological organisms are listed below:

<table><tr><td rowspan=1 colspan=7>Virus Strains Tested for Cross Reactivity with D³ HSV DFA Reagent</td></tr><tr><td rowspan=1 colspan=1>Organism</td><td rowspan=1 colspan=1>Strain orType</td><td rowspan=1 colspan=2>Inoculum(TCID50)</td><td rowspan=1 colspan=1>Organism</td><td rowspan=1 colspan=1>Strain or Type</td><td rowspan=1 colspan=1>Inoculum(TCID50)</td></tr><tr><td rowspan=1 colspan=1>Adenovirus</td><td rowspan=1 colspan=1>Type 1</td><td rowspan=1 colspan=2>715</td><td rowspan=1 colspan=1>Influenza B</td><td rowspan=1 colspan=1>Hong Kong</td><td rowspan=1 colspan=1>715</td></tr><tr><td rowspan=1 colspan=1>Adenovirus</td><td rowspan=1 colspan=1>Type 3</td><td rowspan=1 colspan=2>715</td><td rowspan=1 colspan=1>Influenza B</td><td rowspan=1 colspan=1>Maryland</td><td rowspan=1 colspan=1>715</td></tr><tr><td rowspan=1 colspan=1>Adenovirus</td><td rowspan=1 colspan=1>Type 5</td><td rowspan=1 colspan=2>715</td><td rowspan=1 colspan=1>Influenza B</td><td rowspan=1 colspan=1>Mass</td><td rowspan=1 colspan=1>715</td></tr><tr><td rowspan=1 colspan=1>Adenovirus</td><td rowspan=1 colspan=1>Type 6</td><td rowspan=1 colspan=2>715</td><td rowspan=1 colspan=1>Influenza B</td><td rowspan=1 colspan=1>Taiwan</td><td rowspan=1 colspan=1>715</td></tr><tr><td rowspan=1 colspan=1>Adenovirus</td><td rowspan=1 colspan=1>Type 7</td><td rowspan=1 colspan=2>715</td><td rowspan=1 colspan=1>Influenza B</td><td rowspan=1 colspan=1>GL</td><td rowspan=1 colspan=1>715</td></tr><tr><td rowspan=1 colspan=1>Adenovirus</td><td rowspan=1 colspan=1>Type 8</td><td rowspan=1 colspan=2>715</td><td rowspan=1 colspan=1>Influenza B</td><td rowspan=1 colspan=1>JH-001 isolate</td><td rowspan=1 colspan=1>715</td></tr><tr><td rowspan=1 colspan=1>Adenovirus</td><td rowspan=1 colspan=1>Type 10</td><td rowspan=1 colspan=2>715</td><td rowspan=1 colspan=1>Influenza B</td><td rowspan=1 colspan=1>Russia</td><td rowspan=1 colspan=1>715</td></tr><tr><td rowspan=1 colspan=1>Adenovirus</td><td rowspan=1 colspan=1>Type 13</td><td rowspan=1 colspan=2>715</td><td rowspan=1 colspan=1>RSV</td><td rowspan=1 colspan=1>Long</td><td rowspan=1 colspan=1>715</td></tr><tr><td rowspan=1 colspan=1>Adenovirus</td><td rowspan=1 colspan=1>Type 14</td><td rowspan=1 colspan=2>715</td><td rowspan=1 colspan=1>RSV</td><td rowspan=1 colspan=1>Wash</td><td rowspan=1 colspan=1>715</td></tr><tr><td rowspan=1 colspan=1>Adenovirus</td><td rowspan=1 colspan=1>Type 18</td><td rowspan=1 colspan=2>715</td><td rowspan=1 colspan=1>RSV</td><td rowspan=1 colspan=1>9320</td><td rowspan=1 colspan=1>715</td></tr><tr><td rowspan=1 colspan=1>Adenovirus</td><td rowspan=1 colspan=1>Type 31</td><td rowspan=1 colspan=2>715</td><td rowspan=1 colspan=1>Parainfluenza 1</td><td rowspan=1 colspan=1>C-35</td><td rowspan=1 colspan=1>715</td></tr><tr><td rowspan=1 colspan=1>Adenovirus</td><td rowspan=1 colspan=1>Type 40</td><td rowspan=1 colspan=2>715</td><td rowspan=1 colspan=1>Parainfluenza 2</td><td rowspan=1 colspan=1>Greer</td><td rowspan=1 colspan=1>715</td></tr><tr><td rowspan=1 colspan=1>Adenovirus</td><td rowspan=1 colspan=1>Type 41</td><td rowspan=1 colspan=2>715</td><td rowspan=1 colspan=1>Parainfluenza 3</td><td rowspan=1 colspan=1>C 243</td><td rowspan=1 colspan=1>715</td></tr><tr><td rowspan=1 colspan=1>Influenza A</td><td rowspan=1 colspan=1>Aichi</td><td rowspan=1 colspan=2>715</td><td rowspan=1 colspan=1>Parainfluenza 4a</td><td rowspan=1 colspan=1>M-25</td><td rowspan=1 colspan=1>715</td></tr><tr><td rowspan=1 colspan=1>Influenza A</td><td rowspan=1 colspan=1>Mal</td><td rowspan=1 colspan=2>715</td><td rowspan=1 colspan=1>Parainfluenza 4b</td><td rowspan=1 colspan=1>CH19503</td><td rowspan=1 colspan=1>715</td></tr><tr><td rowspan=1 colspan=1>Influenza A</td><td rowspan=1 colspan=1>Hong Kong</td><td rowspan=1 colspan=2>715</td><td rowspan=1 colspan=1>CMV</td><td rowspan=1 colspan=1>Towne</td><td rowspan=1 colspan=1>700</td></tr><tr><td rowspan=1 colspan=1>Influenza A</td><td rowspan=1 colspan=1>Denver</td><td rowspan=1 colspan=2>715</td><td rowspan=1 colspan=1>CMV</td><td rowspan=1 colspan=1>Davis</td><td rowspan=1 colspan=1>700</td></tr><tr><td rowspan=1 colspan=1>Influenza A</td><td rowspan=1 colspan=1>Port Chalmers</td><td rowspan=1 colspan=2>715</td><td rowspan=1 colspan=1>CMV</td><td rowspan=1 colspan=1>AD169</td><td rowspan=1 colspan=1>700</td></tr><tr><td rowspan=1 colspan=1>Influenza A</td><td rowspan=1 colspan=1>Victoria</td><td rowspan=1 colspan=2>715</td><td rowspan=1 colspan=1>VZV</td><td rowspan=1 colspan=1>Webster</td><td rowspan=1 colspan=1>500</td></tr><tr><td rowspan=1 colspan=1>Influenza A</td><td rowspan=1 colspan=1>New Jersey</td><td rowspan=1 colspan=2>715</td><td rowspan=1 colspan=1>VZV</td><td rowspan=1 colspan=1>Allen</td><td rowspan=1 colspan=1>500</td></tr><tr><td rowspan=1 colspan=1>Influenza A</td><td rowspan=1 colspan=1>PR</td><td rowspan=1 colspan=2>715</td><td rowspan=1 colspan=1>Epstein-Barr</td><td rowspan=3 colspan=2>Commercially available slides stained.1</td></tr><tr><td rowspan=1 colspan=1>Influenza A</td><td rowspan=1 colspan=1>WS</td><td rowspan=1 colspan=2>715</td><td rowspan=1 colspan=1>Rubeola</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=1>Mumps</td></tr><tr><td rowspan=1 colspan=1>Echovirus</td><td rowspan=1 colspan=1>Types 4, 6, 9,11, 30, 34</td><td rowspan=1 colspan=2>Commerciallyavailable slidesstaained.</td><td rowspan=1 colspan=1>HPV</td><td rowspan=1 colspan=1>Types 6, 11</td><td rowspan=1 colspan=1>Commerciallyavailable slidesstaained.</td></tr><tr><td rowspan=1 colspan=1>Coxsackievirus</td><td rowspan=1 colspan=1>Types B1, B2,B3, B4, B5, B6</td><td rowspan=1 colspan=2>Commerciallyavailable slidesstained.</td><td rowspan=1 colspan=3></td></tr><tr><td rowspan=1 colspan=7>Cell Lines Tested for Cross Reactivity with D3 HSV DFA Reagent</td></tr><tr><td rowspan=1 colspan=3>A-549</td><td rowspan=1 colspan=4>NCI-H292</td></tr><tr><td rowspan=1 colspan=3>BGMK</td><td rowspan=1 colspan=4>pCMK</td></tr><tr><td rowspan=1 colspan=3>HEp-2</td><td rowspan=1 colspan=4>pRhMK</td></tr><tr><td rowspan=1 colspan=3>LLC-MK2</td><td rowspan=1 colspan=4>RhMK II</td></tr><tr><td rowspan=1 colspan=3>MDCK</td><td rowspan=1 colspan=4>pRK</td></tr><tr><td rowspan=1 colspan=3>MRC-5</td><td rowspan=1 colspan=4>RD</td></tr><tr><td rowspan=1 colspan=3>MRHF</td><td rowspan=1 colspan=4>R-Mix</td></tr><tr><td rowspan=1 colspan=3>Mv1Lu</td><td rowspan=1 colspan=4>Vero &amp; WI-38</td></tr></table>

<table><tr><td rowspan=1 colspan=2>Microorganisms Tested for Cross Reactivity with D3 HSV DFA Reagent</td></tr><tr><td rowspan=1 colspan=1>BACTERIA</td><td rowspan=1 colspan=1>CFU TESTED</td></tr><tr><td rowspan=1 colspan=1>Acinetobacter calcoaceticus</td><td rowspan=1 colspan=1>9.7 x 105</td></tr><tr><td rowspan=1 colspan=1>Bordetella bronchiseptica</td><td rowspan=1 colspan=1>1.7 x 105</td></tr><tr><td rowspan=1 colspan=1>Bordetella pertussis</td><td rowspan=1 colspan=1>4.6 x 106</td></tr></table>

1 Test material is from commercially available prepared slides. Each positive well contains approximately 10 to $50 \%$ reactive cells.

<table><tr><td rowspan=1 colspan=1>Corynebacterium diphtheriae</td><td rowspan=1 colspan=2>2.5 x 106</td></tr><tr><td rowspan=1 colspan=1>Escherichia coli</td><td rowspan=1 colspan=2>2.6 x 105</td></tr><tr><td rowspan=1 colspan=1>Gardnerella vaginalis</td><td rowspan=1 colspan=2>5.0 x 105</td></tr><tr><td rowspan=1 colspan=1>Haemophilis influenzae type A</td><td rowspan=1 colspan=2>9.3 x 105</td></tr><tr><td rowspan=1 colspan=1>Klebsiella pneumoniae</td><td rowspan=1 colspan=2>6.4 x 106</td></tr><tr><td rowspan=1 colspan=1>Legionella pneumophila</td><td rowspan=1 colspan=1>6.5 x 104</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Moraxella cartarrhalis</td><td rowspan=1 colspan=1>6.4 x 104</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Neisseria gonorrhoeae</td><td rowspan=1 colspan=1>1.3 x 106</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Proteus mirabilis</td><td rowspan=1 colspan=1>2.1 x 106</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Pseudomonas aeruginosa</td><td rowspan=1 colspan=1>1.0 x 107</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Salmonella enteriditis</td><td rowspan=1 colspan=1>2.5 x 106</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Salmonella typhimurium</td><td rowspan=1 colspan=1>1.7 x 106</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Staphylococcus aureus</td><td rowspan=1 colspan=1>1.0 x 107</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Streptococcus agalactiae</td><td rowspan=1 colspan=1>9.6 x 106</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Streptococcus pneumoniae</td><td rowspan=1 colspan=1>8.0 x 105</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Streptococcus pyogenes</td><td rowspan=1 colspan=1>2.9 x 107</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Acholeplasma laidlawi</td><td rowspan=1 colspan=2>~6 x 107</td></tr><tr><td rowspan=1 colspan=1>Mycoplasma hominis</td><td rowspan=1 colspan=2>~6 x 104</td></tr><tr><td rowspan=1 colspan=1>Mycoplasma orale</td><td rowspan=1 colspan=2>~6 x 104</td></tr><tr><td rowspan=1 colspan=1>Mycoplasma pneumoniae</td><td rowspan=1 colspan=2>~6 x 104</td></tr><tr><td rowspan=1 colspan=1>Mycoplasma salivarium</td><td rowspan=1 colspan=2>6 x 107</td></tr><tr><td rowspan=1 colspan=1>Ureaplasma uralyticum</td><td rowspan=1 colspan=2>~6 x 104</td></tr><tr><td rowspan=1 colspan=1>Chlamydophila pneumoniae</td><td rowspan=1 colspan=2>Commercially available slides stained. 1</td></tr><tr><td rowspan=1 colspan=1>Chlamydia trachomatis</td><td rowspan=1 colspan=2>Commercially available slides stained. 1</td></tr><tr><td rowspan=1 colspan=1>YEAST</td><td rowspan=1 colspan=2></td></tr><tr><td rowspan=1 colspan=1>Candida glabrata</td><td rowspan=1 colspan=2>8.7 x 106</td></tr><tr><td rowspan=1 colspan=1>PROTOZOAN</td><td rowspan=1 colspan=2></td></tr><tr><td rowspan=1 colspan=1>Trichomonas vaginalis</td><td rowspan=1 colspan=2>[Commercially available slides stained.]</td></tr></table>

f. Assay cut-off: Not-applicable.

3. Comparison studies:

a. Method comparison with predicate device: This study included four hundred and one (401) prospectively collected specimens submitted for Herpes simplex culture. Each specimen was evaluated by the Diagnostic Hybrids ${ \boldsymbol { \mathrm { D } } } ^ { 3 }$ DFA Herpes Simplex Virus Identification and Typing Kit ( ${ } ^ { 6 6 } { \mathrm { D } } ^ { 3 }$ DFA HSV ID & Typing Kit”) and compared to a currently marketed HSV identification kit (“Comparison Device”). A combination of fresh (154) and frozen (247) specimens were tested. Three specimens from site 3 were not evaluated due to bacterial contamination of the monolayers, leaving 398 for analysis. These studies were conducted at two external laboratory sites located in the midwest United States and one in-house virology laboratory.

Percent Agreement between the ${ \boldsymbol { \mathrm { D } } } ^ { 3 }$ DFA HSV ID & Typing Kit and the Comparison Devices was calculated and tabulated for all the tested specimens, and is presented below. The term, $9 5 \%$ CI” refers to $9 5 \%$ Confidence Intervals, which were calculated according to Exact method (Clopper, C. and S. Pearson, Biometrika 26:404-413, 1934).

# Results from Testing of All Specimens:

Total results - ${ \boldsymbol { \mathrm { D } } } ^ { 3 }$ DFA HSV ID & Typing Kit and comparison device using various culture methodologies.

<table><tr><td></td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>73</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>b</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>76</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>324</td><td rowspan=1 colspan=1>b</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>321</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>95% CI</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>95% CI</td></tr><tr><td rowspan=1 colspan=1>73/7498.6%</td><td rowspan=1 colspan=2>92.7% - 100%</td><td rowspan=1 colspan=1>b</td><td rowspan=1 colspan=1>76/76100%</td><td rowspan=1 colspan=2>95.3% - 100%</td></tr><tr><td rowspan=1 colspan=1>324/324100%</td><td rowspan=1 colspan=2>98.9% - 100%</td><td rowspan=1 colspan=1>b</td><td rowspan=1 colspan=1>321/32299.7%</td><td rowspan=1 colspan=2>98.3% -100%</td></tr></table>

# Results from Individual Study Sites:

i. Study Site 1: A total of 107 specimens (4 fresh and 103 frozen) were tested using the ${ \boldsymbol { \mathrm { D } } } ^ { 3 }$ DFA HSV ID & Typing Kit. An aliquot from each specimen was inoculated into MRC-5 and A549 tubes, one tube for each HSV type. The inoculated cells were incubated at $3 5 ^ { \circ }$ to $3 7 ^ { \circ } \mathrm { C }$ and examined daily for CPE for seven days. Tube cultures exhibiting no CPE after seven days of incubation were scraped and cell spots made on multiwell slides. The cell spots were fixed with acetone and in accordance with the respective product insert (subject and predicate devices). All calculations for confidence intervals were done according to the Exact Method. The results of comparison testing are summarized below (Table 6).

<table><tr><td rowspan="2"></td><td colspan="3">Table 6a - HSV-1 Comparison Device</td></tr><tr><td></td><td>+</td><td></td></tr><tr><td rowspan="4">D^³ DFA HSV ID &amp; Typing Kit PPA =</td><td>+</td><td>35</td><td>0</td></tr><tr><td></td><td>0</td><td>72</td></tr><tr><td></td><td>95% CI</td><td></td></tr><tr><td>35/35 100%</td><td>90.0% - 100%</td><td></td></tr><tr><td>NPA =</td><td>72/72 100%</td><td>95.0% - 100%</td><td></td></tr></table>

<table><tr><td rowspan=2 colspan=3>Table 6b  HSV-2Comparison Device+</td></tr><tr><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>28</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>79</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>95% CI</td></tr><tr><td rowspan=1 colspan=1>28/28100%</td><td rowspan=1 colspan=2>87.7% - 100%</td></tr><tr><td rowspan=1 colspan=1>79/79100%</td><td rowspan=1 colspan=2>95.4% - 100%</td></tr></table>

ii. Study Site 2: A total of 150 fresh specimens were cultured for HSV. Briefly, an aliquot from each specimen was inoculated into MRC-5 tubes, one tube for each HSV type. The inoculated cells were incubated at $3 5 ^ { \circ }$ to $3 7 ^ { \circ } \mathrm { C }$ and examined daily for CPE. Tube cultures exhibiting CPE were scraped and cell spots made on multi-well slides according to the ${ \boldsymbol { \mathrm { D } } } ^ { 3 }$ DFA HSV ID & Typing Kit and Comparison Device product insert procedures. Tube cultures exhibiting no CPE at 7-days were also scraped and cell spots made to confirm the absence of HSV. All 150 specimens were tested for the presence of HSV. All calculations for confidence intervals were done according to the Exact Method. The results of this testing site are summarized below (Table 7).

<table><tr><td rowspan="2"></td><td colspan="3">Table 7a - HSV-1 Comparison Device</td></tr><tr><td></td><td>+</td><td></td></tr><tr><td rowspan="3">D3 DFA HSV ID &amp; Typing Kit</td><td>+</td><td>21</td><td>0</td></tr><tr><td></td><td>1</td><td>128</td></tr><tr><td></td><td>95% CI</td><td></td></tr><tr><td rowspan="3">PPA = NPA =</td><td>21/22 95.5%</td><td colspan="2">77.2% - 99.9%</td></tr><tr><td>128/128</td><td>97.2% - 100%</td><td></td></tr><tr><td>100%</td><td colspan="2"></td></tr></table>

<table><tr><td rowspan=2 colspan=3>Table 7b - HSV-2Comparison Device+</td></tr><tr><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>124</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>95% CI</td></tr><tr><td rowspan=1 colspan=1>25/25100%</td><td rowspan=1 colspan=2>86.3% - 100%</td></tr><tr><td rowspan=1 colspan=1>124/12599.2%</td><td rowspan=1 colspan=2>95.6% - 100%</td></tr></table>

iii. Study Site 3: The study was conducted at a Diagnostic Hybrids in-house virology laboratory. A total of 141 frozen specimens provided by an independent laboratory were processed. An aliquot from each specimen was inoculated into duplicate wells of DHI H&V-Mix™ multi-well plates. The inoculated cells were centrifuged, incubated up to 24-hours then stained in accordance with the respective product insert. All calculations for confidence intervals were done according to the Exact Method. The results of this testing are summarized below (Table 8).

<table><tr><td colspan="4">Table 8a - HSV-1</td></tr><tr><td colspan="2"></td><td>Comparison Device +</td><td></td></tr><tr><td rowspan="3">D^³ DFA HSV ID &amp; Typing Kit</td><td>+</td><td>17</td><td>0</td></tr><tr><td></td><td>0</td><td>124</td></tr><tr><td></td><td colspan="2">95% CI</td></tr><tr><td rowspan="3">PPA = NPA =</td><td>17/17 100%</td><td colspan="2">80.5% - 100%</td></tr><tr><td>124/124</td><td colspan="2">97.1% - 100%</td></tr><tr><td>100%</td><td colspan="2"></td></tr></table>

<table><tr><td rowspan=2 colspan=3>Table 8b - HSV-2Comparison Device+</td></tr><tr><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>23</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>118</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>95% CI</td></tr><tr><td rowspan=1 colspan=1>23/23100%</td><td rowspan=1 colspan=2>85.2% - 100%</td></tr><tr><td rowspan=1 colspan=1>118/118100%</td><td rowspan=1 colspan=2>96.9% - 100%</td></tr></table>

b. Matrix comparison: Not applicable

4. Clinical studies: Testing was performed with clinically collected specimens submitted to the four different laboratories for HSV testing. Results were compared with a legally marketed HSV device(s).

a. Clinical Sensitivity: Not applicable.   
b. Clinical specificity: Not applicable.   
c. Other clinical supportive data: Not applicable.

5. Clinical cut-off: Not applicable.

6. Expected values/Reference range: Not applicable.

N. Proposed Labeling: The labeling is considered adequate and satisfies the requirements of 21 CFR Part 809.10 for safety and effectiveness and substantial equivalence to a legally marketed device.

O. Conclusion: The submitted information in this premarket notification is considered complete and supports a substantial equivalence decision.